ClinicalTrials.gg
CompletedNCT02468700Updated Mar 29, 2018Results posted

OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye

A Phase 2 interventional study of Dexamethasone and Placebo Vehicle in Dry Eye, sponsored by Ocular Therapeutix, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-29.

Sponsored by Ocular Therapeutix, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2015, registered Jun 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing dexamethasone in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. Dexamethasone · Dry Eye Syndromes.

Enrollment
6th of 16
43 · median 36
Started
2015
the only one that year
Phase 2
2 of 16
none open now
Registered
4th of 16
by date
Lead sponsor
1 of 16
Ocular Therapeutix, Inc.

Among the 16 studies testing dexamethasone in Dry Eye Syndromes, this one is the 6th largest by enrollment, is the only one that started in 2015, is one of 2 in phase 2, and was the 4th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

None of the 16 studies testing dexamethasone in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →

Where they have run

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing dexamethasone in Dry Eye Syndromes as a file.
02

Study summary

The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of dry eye disease

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Had a known history of dry eye disease
  • Had a minimal Corneal Fluorescein Staining Score and OSDI score in each eye

Exclusion criteria

Exclusion Criteria:

  • History of intraocular inflammation in either eye
  • Use of the anti-inflammatory or immunomodulating agents ocular or systemic for the duration of the study
  • Uncontrolled glaucoma or is on medications to treat glaucoma
  • History of IOP spikes in either eye
  • Active epiphora
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    OTX-DP

    OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use

    Drug: Dexamethasone

  • Placebo comparator
    PV

    PV (placebo drug delivery vehicle)

    Other: Placebo Vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Total Corneal Fluorescein Staining

    National Eye Institute (NEI) Scale; Grade 0-3 for each region, 5 regions total (Total maximum score=15; 0=No staining)

    Time frame: Day 15

  2. Total Corneal Fluorescein Staining

    National Eye Institute (NEI) Scale; Grade 0-3 for each region, 5 regions total (Total maximum score=15; 0=No staining)

    Time frame: Day 30

  3. Total Conjunctival Lissamine Green Staining

    National Eye Institute (NEI) Scale; Grade 0-3 for each region, 6 regions total (Total maximum score=18; 0=No staining)

    Time frame: Day 15

  4. Total Conjunctival Lissamine Green Staining

    National Eye Institute (NEI) Scale; Grade 0-3 for each region, 6 regions total (Total maximum score=18; 0=No staining)

    Time frame: Day 30

07

Results

Posted Mar 29, 2018

Participant flow

Participant flow — Overall Study
MilestoneOTX-DPPlacebo Vehicle
Started2221
Completed2019
Not completed22

Outcome measures

PrimaryTotal Corneal Fluorescein Staining

National Eye Institute (NEI) Scale; Grade 0-3 for each region, 5 regions total (Total maximum score=15; 0=No staining)

Time frame:
Day 15
Reported as:
Mean · units on a scale
Total Corneal Fluorescein Staining
units on a scaleOTX-DPPlacebo Vehicle
Total Corneal Fluorescein Staining4.09 ± 2.6715.05 ± 3.041
PrimaryTotal Corneal Fluorescein Staining

National Eye Institute (NEI) Scale; Grade 0-3 for each region, 5 regions total (Total maximum score=15; 0=No staining)

Time frame:
Day 30
Reported as:
Mean · units on a scale
Total Corneal Fluorescein Staining
units on a scaleOTX-DPPlacebo Vehicle
Total Corneal Fluorescein Staining4.64 ± 2.3616.38 ± 3.278
PrimaryTotal Conjunctival Lissamine Green Staining

National Eye Institute (NEI) Scale; Grade 0-3 for each region, 6 regions total (Total maximum score=18; 0=No staining)

Time frame:
Day 15
Reported as:
Mean · units on a scale
Total Conjunctival Lissamine Green Staining
units on a scaleOTX-DPPlacebo Vehicle
Total Conjunctival Lissamine Green Staining4.36 ± 2.5175.67 ± 4.199
PrimaryTotal Conjunctival Lissamine Green Staining

National Eye Institute (NEI) Scale; Grade 0-3 for each region, 6 regions total (Total maximum score=18; 0=No staining)

Time frame:
Day 30
Reported as:
Mean · units on a scale
Total Conjunctival Lissamine Green Staining
units on a scaleOTX-DPPlacebo Vehicle
Total Conjunctival Lissamine Green Staining6.41 ± 2.1307.81 ± 3.642

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OTX-DP0/22 (0%)1/22 (4.5%)15/22 (68.2%)
Placebo Vehicle0/21 (0%)0/21 (0%)11/21 (52.4%)
Most frequent serious events
Most frequent serious events
EventOTX-DPPlacebo Vehicle
Myocardial infarctionCardiac disorders1/220/21
Most frequent other events
Most frequent other events
EventOTX-DPPlacebo Vehicle
Adverse EventsGeneral disorders15/2211/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)OTX-DPPlacebo VehicleTotal
Mean62.3 (41 to 84)62.5 (46 to 77)62.4 (41 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)OTX-DPPlacebo VehicleTotal
Female131730
Male9413
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OTX-DPPlacebo VehicleTotal
Hispanic or Latino213
Not Hispanic or Latino202040
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OTX-DPPlacebo VehicleTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White212041
More than one race000
Unknown or Not Reported011
Iris Color
Iris Color(Participants)OTX-DPPlacebo VehicleTotal
Blue51015
Brown8715
Hazel7310
Green213
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Aug 2015, 7 months.

Results were first posted in Mar 2018, 2 years 7 months after primary completion.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 7 months is close to that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2015
First posted
Jun 11, 2015
StartActual
Jan 2015
Primary completionActual
Aug 2015
CompletionActual
Nov 2015
Results first posted
Mar 29, 2018
Last update
Mar 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02468700
Collaborators
ORA, Inc.
Responsible party
Sponsor
First posted
Jun 11, 2015
Start date
Jan 2015
Primary completion
Aug 2015
Completion
Nov 2015
Results posted
Mar 29, 2018
Last update
Mar 29, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion